We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

6 hedge funds and large institutions have $175K invested in XTL Biopharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 6 → 6 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.67% less ownership

Funds ownership: 3.74% → 3.07% (-0.67%)

8% less capital invested

Capital invested by funds: $191K → $175K (-$15.5K)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SP
SmartHarvest Portfolios
Washington
+$42.3K
2
TRCT
Tower Research Capital (TRC)
New York
+$774
3
GI
GAMMA Investing
California
+$526

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$44K
2
XT
XTX Topco
Cayman Islands
-$5.94K
3
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$4.88K
4
Morgan Stanley
Morgan Stanley
New York
-$1.35K

XTLB Hedge Fund Activity: Q1 2026 in Review

6 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2026, worth a combined $175K — down 8.1% from $191K a quarter earlier.

Fund positioning in XTLB was balanced in Q1 2026: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was SmartHarvest Portfolios, opening a new position worth an estimated $42.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $44K sold.

  • 6 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2026, unchanged from Q4 2025.
  • Funds reported $175K of XTL Biopharmaceuticals stock for Q1 2026, down 8.1% quarter-over-quarter.
  • 2 funds opened new XTL Biopharmaceuticals positions in Q1 2026 and 2 closed out, a net change of 0 holders.
  • The largest XTL Biopharmaceuticals buyer in Q1 2026 was SmartHarvest Portfolios, an estimated $42.3K added.
  • The largest XTL Biopharmaceuticals seller in Q1 2026 was Citadel Advisors, an estimated $44K sold.

Based on aggregated 13F filings for Q1 2026.